Informazioni aggiornate sullo stato dell'arte del tumore del pancreas viste attraverso gli occhi dei pazienti Italian Pancreatic Cancer Advocacy Organization
Milano, Lombardia
Joined May 2016
- Tweets1.4K
- Following235
- Followers424
- Likes2.7K
We have advocated for the same idea on the irinotecan vs Nal-iri for over three years. We are astonished to read somebody talking of a practice-changing protocol.
Read the news that NALIRIFOX got approved today by the FDA. Don’t be misled to believe that this represents any innovation. This is a pseudo innovation for which you get to pay more without any added benefits. We discuss this and other pancreatic cancer treatments in our recent @TheLancetOncol essay:
thelancet.com/journals/lanon…
The article confirms that NALIRIFOX is not better than FOLFIRINOX against a considerably higher price of NALIRIFOX compared to FOLFIRINOX
Our work is out on @JAMANetworkOpen ❗️
Is NALIRIFOX better than FOLFIRINOX as 1st line for metastatic #pancsm ❓
❎similar OS and PFS,
⚠️different clinical and 💰 toxicity
“I suppose we all thought that one way or another” jamanetwork.com/journals/jam…
In un mondo che vive di aneddoti c'è un gran bisogno di conoscenza e esperienza in questo ambito in
🎓 Annunciazione annunciazione!
La prossima edizione del nostro Master in #Statistica per la #RicercaClinica e #Epidemiologia è in arrivo! 🚀
Diffondi la voce ed entra in contatto con noi!
🌐 Resta aggiornato per il bando ufficiale.
#Master2023 #FormazioneAccademica
GIORNATA MONDIALE TUMORE DEL PANCREAS
Il nostro contributo con un video su un percorso di cura a cui tutti i pazienti dovrebbero avere accesso:
bit.ly/WPCD-23-CV
Video realizzato con soli strumenti di AI
@headlighty @AISP_Pancreas
That's the way ...
In @JCOCCI_ASCO
Real-Time Identification of #PancreaticCancer Cases Using Artificial Intelligence Developed on Danish Nationwide Registry Data
ascopubs.org/doi/abs/10.1200…
The machine learning algorithm used here was able to identify high risk groups with a 10.1% risk of being diagnosed with pancreatic cancer within 1 year, anticipating diagnosis by ~5 months. The benefit to an algorithm like this is that it could be applicable in a primary care setting where patients often spend months in being worked up before a scan is ordered that identifies a pancreatic mass. A few months anticipation in diagnosis might be the difference between surgically resectable and unresectable cancers. Would love to see how real world implementation of algorithms like this result in meaningful stage shifts.
L'ambiente accademico è uno degli ambiti professionali più chiusi che si possa immaginare.
I wonder what postmortem @Penn is doing, given their past mistake: "UPenn told me that they’d had a meeting and concluded that I was not of faculty quality. When I told them I was leaving, they laughed at me and said, ‘BioNTech doesn’t even have a website.’"
Codice Viola retweeted
Crowds gather to hear @EileenMOReilly @MSKCancerCenter talk on the immunological correlatives of @ElicioTx amphiphilic lymph node targeted vaccine directed against mutant KRAS in surgically resected #PancreaticCancer (and #ColorectalCancer) with ctDNA or CA19-9 positive minimal residual disease (AMPLIFY-201).
The key data (albeit small numbers, limited follow up) is very similar to what was observed with mRNA vaccine in adjuvant setting - there is a subset of patients (around 50%) who generate potent T cell responses to the vaccine and these individuals do very well on the recurrence free survival scale. Then there is a subset (remaining 50%) that do not develop robust T cell responses and unfortunately those patients progress fairly rapidly. Now we need to figure - pre facto, not post - what differentiates the individuals who develop productive T cell responses from the ones who do not. #AACRPan23
@DrShubhamPant @MDAndersonNews
Codice Viola retweeted
#AACRPan23 talk by Dr. Gulam Manji @columbiacancer on CheMoMETPANC 👉🏽 gemcitabine plus nab-paclitaxel + motixafortide (CXCR4 antagonist) + cemiplimib in advanced #PancreaticCancer. Responses observed in both primary & metastatic sites, with 64% partial responses & 27% stable disease. All patients in the trial received paired biopsies for deep correlative studies. Now moving to randomized phase 2.
Codice Viola retweeted
#TumorBoardTuesday
Thursday wrap up!
@CentralParkWMD @ferguskeane2 led the discussion. More and more, molecular 🎯 different options in #PDAC.
✅HRD- PARPi; always want to go for curative surg if possible, but in met or 2L setting
✅KRAS- G12C small # of cases, G12D inhibs in trials
**Claudin18.2 emerging**
🆓#CME credit-2 quick❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval23
The relapse rate is another uncharted territory in the article.
Word of caution on artery rsxn for PDAC: 1)These series reflect significant selection over decades where denominators not known. 2) Survival not clearly improved vs just chemo 3) high recurrence 4)high mortality and morbidity.@bjs @DrJashDatta academic.oup.com/bjs/article…
So true!!
“If we could change the diagnostic odyssey, we could actually change the power balance of patients in the health-care system”
- @TaniaSimoncelli, VP Science in Society @cziscience
Grazie a Pieve _Skin, un'incredibile comunità di parenti e amici di Paolo Campanini tutti determinati a portare avanti le idee di Paolo.
Grazie alla Regione Emilia Romagna, @RegioneER, per l'ascolto, l'ospitalità e l'impegno a migliorare le cure oncologiche
#Sanità. #Solidarietà, il gruppo “#PieveSkin” ha consegnato oggi in #RegioneER un assegno da 15mila euro in favore dell’associazione #CodiceViola, che da anni aiuta i malati di #tumore al #pancreas e le loro famiglie. La #notizia 👉 regioneer.it/SolidarietaPiev…
Widespread issue
Last year, I was offered a job even after disclosing a stage IV cancer diagnosis. Highlighting the very best of workplace acceptance and culture.
But today, my husband unexpectedly had a job offer rescinded after letting the company know he may need 2 days off, a month after starting to help me recover from a possible minor surgery.
We’re both software engineers and both companies are in the healthcare space. The response he received highlights the discrimination that not only many patients face but also their caregivers.
I’d be lying if I said I wasn’t disheartened and frustrated by their response. When faced with the choice, be company A not company B.
We’ve faced bigger hurdles and come out on top, so on we go.
In other news, if anyone is looking to hire a talented software engineer w/experience in healthcare. I know a guy 😉
Here’s a photo of us on my birthday this year. We celebrated with a hackathon building tools/apps for cancer patients. Yes, that was my actual birthday request. Things get real nerdy around here.
VACCINI E TUMORE DEL PANCREAS
Finalmente degli spiragli seri per delle potenziali opzioni di cura per una patologia per la quale da dieci anni non ci sono stati progressi terapeutici significativi
Vaccine boosts T cells that target pancreatic tumours. Read about this clinical trial in a super N&V by @AmandaHuffPhD & @NeehaZaidi go.nature.com/44Iao5b
Bella differenza rispetto a tanti presunti scienziati
"We are not making science for science. We are making science for the benefit of humanity."
This #WorldHealthDay we celebrate Françoise Barré-Sinoussi, awarded the 2008 Nobel Prize in Physiology or Medicine for her role in the discovery of human immunodeficiency (HIV) virus.
Codice Viola retweeted
Regionalization of #PDAC treatment can improve outcomes, but barriers must be considered.
Addressing the barriers is crucial for successful implementation of regionalization policies.
(via Textbook of #PancreaticCancer @ksoreide)
#QualityofCancerCare #neglectedcancers @my_ueg
Codice Viola retweeted
Shedding light on a largely underestimated topic: #Cancer burden in #adolescents and young adults in Europe. Just published in @ESMO_Open by @myESMO esmoopen.com/article/S2059-7…
TUMORE PANCREAS, OLAPARIB E AIFA
Dopo la nostra intervista, la nota AIFA sulla non rimborsabilità del farmaco Olaparib, Michele Reni, oncologo di riferimento sul tumore pancreas, confuta @Aifa_ufficiale con dati clinicamente significativi
bit.ly/Ol-AIFA-RE
